High prevalence of T cell type I protein kinase a deficiency in systemic lupus erythematosus

被引:0
|
作者
Kammer, GM [1 ]
机构
[1] Wake Forest Univ, Sch Med, Dept Internal Med, Rheumatol Sect, Winston Salem, NC 27157 USA
来源
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 07期
关键词
D O I
10.1002/1529-0131(199907)42:7<1458::AID-ANR20>3.0.CO;2-P
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To estimate the prevalence of protein kinase A type I isozyme (PKA-I) deficiency in a cohort of systemic lupus erythematosus (SLE) patients, and to establish whether the isozyme deficiency is associated with SLE disease activity. Methods. Thirty-five SLE patients and 35 age-, sex-, and race-matched normal controls were studied. Fifteen subjects were restudied on at least 3 occasions over a 1-year interval. Clinical disease activity was estimated by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and the T cell activation markers CD25+ and HLA-DR+ were quantified by flow cytometry. PKA-I isozyme activities were quantified in enriched T cells. Statistical analyses were performed by Student's t-test, Mann Whitney U test, and Pearson product moment test. Results. The mean PKA-I activity in SLE T cells (540 pmoles/minute/mg of protein) was significantly lower than that in control T cells (1,578 pmoles/minute/mg of protein) (P < 0.001). The prevalence of isozyme deficiency in this cohort mas 80%. During a l-year interval, PKA-I activities remained significantly reduced, whereas SLEDAI scores significantly improved. There was no relationship between deficient PKA-I activity and either SLEDAI scores or the proportion of T cells bearing CD25+ or HLA-DRS activation markers. Conclusion. There is a high prevalence of deficient T cell PKA-I isozyme activity in SLE that persists over time and is independent of SLE disease activity.
引用
收藏
页码:1458 / 1465
页数:8
相关论文
共 50 条
  • [21] Type I interferon in the pathogenesis of systemic lupus erythematosus
    Postal, Mariana
    Vivaldo, Jessica F.
    Fernandez-Ruiz, Ruth
    Paredes, Jacqueline L.
    Appenzeller, Simone
    Niewold, Timothy B.
    CURRENT OPINION IN IMMUNOLOGY, 2020, 67 : 87 - 94
  • [22] Targeting type I interferon in systemic lupus erythematosus
    Timothy B. Niewold
    Nature Reviews Rheumatology, 2016, 12 : 377 - 378
  • [23] Systemic lupus erythematosus and the type I interferon system
    Lars Rönnblom
    Gunnar V Alm
    Arthritis Res Ther, 5
  • [24] Cyclophosphamide type I hypersensitivity in systemic lupus erythematosus
    Thong, BYH
    Leong, KP
    Thumboo, J
    Koh, ET
    Tang, CY
    LUPUS, 2002, 11 (02) : 127 - 129
  • [25] The genetics of type I interferon in systemic lupus erythematosus
    Bronson, Paola G.
    Chaivorapol, Christina
    Ortmann, Ward
    Behrens, Timothy W.
    Graham, Robert R.
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (05) : 530 - 537
  • [26] Type-I interferons and systemic lupus erythematosus
    Koutouzov, Sophie
    Mathian, Alexis
    Dalloul, Ali
    AUTOIMMUNITY REVIEWS, 2006, 5 (08) : 554 - 562
  • [27] Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling
    Grammatikos, Alexandros P.
    Ghosh, Debjani
    Kyttaris, Vasileios C.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1154 - S1154
  • [28] Type I Interferon Signature in Systemic Lupus Erythematosus
    Bezalel, Shira
    Guri, Keren Mahlab
    Elbirt, Daniel
    Asher, Ilan
    Sthoeger, Zev Moshe
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (04): : 246 - 249
  • [29] Systemic lupus erythematosus and the type I interferon system
    Rönnblom, L
    Alm, GV
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (02) : 68 - 75
  • [30] Targeting type I interferon in systemic lupus erythematosus
    Niewold, Timothy B.
    NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (07) : 377 - U13